Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVX-060 · 1 trial · 5 indications
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to CVX-060 was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CVX-060 | BIOLOGICAL | Weekly, intravenous dose |
Inclusion Criteria: * Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy. * Adequate coagulation, liver, and renal function. * Candidate for DCE-MRI evaluations. * ECOG (Eastern Cooperative Oncology Group) performance status of 0 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CVX-060 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors, including neoplasms, carcinoma, cancer, and malignancy. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
CVX-060 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. It is being evaluated for its safety and pharmacokinetics in patients with advanced solid tumors.
CVX-060 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE.
CVX-060 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Its clinical program consists of one completed Phase 1 trial.
CVX-060 has been studied in one clinical trial, identified as NCT00879684, titled 'Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors.' This Phase 1 trial enrolled 34 participants in the United States and has been completed.
CVX-060 is not known to have alternative names. It is a distinct investigational monoclonal antibody developed by Pfizer, Inc. for advanced solid tumors.